Clinical trial with an "European Community marked" medical device in patients with ischemic heart disease and clinical indication of coronary revascularization with drug-eluting stent.

Clinical follow-up will be done according to this way: first month telephone or face-to-face interview and at 6 ± 1 month an Angiography follow up + OCT (optical coherence tomography)

A randomized clinical trial to compare the efficacy of Angiolite Stent versus a second-generation drug-eluting stent such as Xience stent.(non-inferiority design)

Inclusion Criteria:

• Patients with clinical or subclinical ischemic heart disease with indication of percutaneous revascularization.
• "De Novo" lesions ≥ 70%
• Reference diameters ≥ 2 mm and ≤ 4 mm Accepted participation in the registration with the signing of informed consent

Exclusion Criteria:

• Cardiogenic shock
• Pregnancy
• Intolerance or allergy to anti platelet or anticoagulant therapy
• Elective surgical procedure scheduled within 6 months after inclusion in the study
• Expectancy of life of less than 1 year.
• Impossibility of doing 1 year clinical follow-up.
• Primary angioplasty in patients with killip class III-IV or mechanical complications.
• Patient with pre-procedure restenosis.
• Patients who will not be treated all lesions with the Angiolite stent.
• Total occlusions
• Truncus disease